Acne Vulgaris - Pipeline Review, H2 2015

Date: October 30, 2015
Pages: 186
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A1FF4E1E589EN
Leaflet:

Download PDF Leaflet

Acne Vulgaris - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Acne Vulgaris - Pipeline Review, H2 2015’, provides an overview of the Acne Vulgaris’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acne Vulgaris and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acne Vulgaris pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Acne Vulgaris Overview
Therapeutics Development
Pipeline Products for Acne Vulgaris - Overview
Pipeline Products for Acne Vulgaris - Comparative Analysis
Acne Vulgaris - Therapeutics under Development by Companies
Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes
Acne Vulgaris - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acne Vulgaris - Products under Development by Companies
Acne Vulgaris - Products under Investigation by Universities/Institutes
Acne Vulgaris - Companies Involved in Therapeutics Development
3SBIO INC.
Advancell
Allergan Plc
Almirall, S.A.
Biomar Microbial Technologies
Braintree Laboratories, Inc.
Brickell Biotech, Inc.
Celtaxsys, Inc.
Cosmo Pharmaceuticals S.p.A
Delenex Therapeutics AG
Deltanoid Pharmaceuticals Inc.
DermaXon, LLC
Dermira Inc.
ELORAC, Inc.
Ensol Biosciences Inc.
Foamix Pharmaceuticals Ltd.
Galderma S.A.
GlaxoSmithKline Plc
Helix BioMedix, Inc.
Hovione FarmaCiencia SA
Lee's Pharmaceutical Holdings Limited
Maruho Co., Ltd.
Novabiotics Limited
Novan, Inc.
OrigImm e.U.
Paratek Pharmaceuticals, Inc.
Phosphagenics Limited
Photocure ASA
Promius Pharma, LLC
Provectus Biopharmaceuticals, Inc.
RestorGenex Corporation
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
SkyePharma Plc
Telesso Technologies Limited
Thesan Pharmaceuticals, Inc.
Toyama Chemical Co., Ltd.
Valeant Pharmaceuticals International, Inc.
Venn Life Sciences Holdings Plc
Vyome Biosciences Private Limited
Xenon Pharmaceuticals Inc.
Acne Vulgaris - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(adapalene + benzoyl peroxide) - Drug Profile
(adapalene + clindamycin hydrochloride) - Drug Profile
(clindamycin phosphate + tretinoin) - Drug Profile
acebilustat - Drug Profile
Aczone X - Drug Profile
AD-037 - Drug Profile
aminolevulinic acid hydrochloride - Drug Profile
ANs-29 - Drug Profile
AQ-401 - Drug Profile
B-244 - Drug Profile
BBI-3000 - Drug Profile
becocalcidiol - Drug Profile
benzoyl peroxide - Drug Profile
benzoyl peroxide - Drug Profile
BLI-1100 - Drug Profile
CB-0301 - Drug Profile
CB-0604 - Drug Profile
DFD-10 - Drug Profile
DLX-2323 - Drug Profile
DLX-2681 - Drug Profile
DRM-01 - Drug Profile
Drugs for Acne - Drug Profile
DX-0385 - Drug Profile
E-10215 - Drug Profile
finasteride - Drug Profile
FMX-101 - Drug Profile
GSK-1940029 - Drug Profile
HB-1345 - Drug Profile
Hesed-4000 - Drug Profile
IB-07A037 - Drug Profile
IDP-120 - Drug Profile
IDP-121 - Drug Profile
IDP-123 - Drug Profile
methyl aminolevulinate hydrochloride - Drug Profile
minocycline - Drug Profile
minocycline - Drug Profile
MTC-896 - Drug Profile
NAI-003 - Drug Profile
NVN-1000 - Drug Profile
omiganan pentahydrochloride - Drug Profile
onabotulinumtoxin A - Drug Profile
ozenoxacin - Drug Profile
Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile
PH-10 - Drug Profile
RES-440 - Drug Profile
sarecycline hydrochloride - Drug Profile
SKP-026 - Drug Profile
Small Molecule for Acne and Skin Inflammation - Drug Profile
SYN-1113 - Drug Profile
Synthetic Peptide for Acne Vulgaris - Drug Profile
Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile
tretinoin - Drug Profile
trifarotene - Drug Profile
Vaccine for Acne Vulgaris - Drug Profile
Vaccine for Acne Vulgaris - Drug Profile
VB-1953 - Drug Profile
XEN-801 - Drug Profile
Acne Vulgaris - Recent Pipeline Updates
Acne Vulgaris - Dormant Projects
Acne Vulgaris - Discontinued Products
Acne Vulgaris - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acne Vulgaris, H2 2015
Number of Products under Development for Acne Vulgaris - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Acne Vulgaris - Pipeline by 3SBio Inc., H2 2015
Acne Vulgaris - Pipeline by Advancell, H2 2015
Acne Vulgaris - Pipeline by Allergan Plc, H2 2015
Acne Vulgaris - Pipeline by Almirall, S.A., H2 2015
Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H2 2015
Acne Vulgaris - Pipeline by Braintree Laboratories, Inc., H2 2015
Acne Vulgaris - Pipeline by Brickell Biotech, Inc., H2 2015
Acne Vulgaris - Pipeline by Celtaxsys, Inc., H2 2015
Acne Vulgaris - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2015
Acne Vulgaris - Pipeline by Delenex Therapeutics AG, H2 2015
Acne Vulgaris - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2015
Acne Vulgaris - Pipeline by DermaXon, LLC, H2 2015
Acne Vulgaris - Pipeline by Dermira Inc., H2 2015
Acne Vulgaris - Pipeline by ELORAC, Inc., H2 2015
Acne Vulgaris - Pipeline by Ensol Biosciences Inc., H2 2015
Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Acne Vulgaris - Pipeline by Galderma S.A., H2 2015
Acne Vulgaris - Pipeline by GlaxoSmithKline Plc, H2 2015
Acne Vulgaris - Pipeline by Helix BioMedix, Inc., H2 2015
Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H2 2015
Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015
Acne Vulgaris - Pipeline by Maruho Co., Ltd., H2 2015
Acne Vulgaris - Pipeline by Novabiotics Limited, H2 2015
Acne Vulgaris - Pipeline by Novan, Inc., H2 2015
Acne Vulgaris - Pipeline by OrigImm e.U., H2 2015
Acne Vulgaris - Pipeline by Paratek Pharmaceuticals, Inc., H2 2015
Acne Vulgaris - Pipeline by Phosphagenics Limited, H2 2015
Acne Vulgaris - Pipeline by Photocure ASA, H2 2015
Acne Vulgaris - Pipeline by Promius Pharma, LLC, H2 2015
Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015
Acne Vulgaris - Pipeline by RestorGenex Corporation, H2 2015
Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015
Acne Vulgaris - Pipeline by SkyePharma Plc, H2 2015
Acne Vulgaris - Pipeline by Telesso Technologies Limited, H2 2015
Acne Vulgaris - Pipeline by Thesan Pharmaceuticals, Inc., H2 2015
Acne Vulgaris - Pipeline by Toyama Chemical Co., Ltd., H2 2015
Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015
Acne Vulgaris - Pipeline by Venn Life Sciences Holdings Plc, H2 2015
Acne Vulgaris - Pipeline by Vyome Biosciences Private Limited, H2 2015
Acne Vulgaris - Pipeline by Xenon Pharmaceuticals Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Acne Vulgaris Therapeutics - Recent Pipeline Updates, H2 2015
Acne Vulgaris - Dormant Projects, H2 2015
Acne Vulgaris - Dormant Projects (Contd..1), H2 2015
Acne Vulgaris - Dormant Projects (Contd..2), H2 2015
Acne Vulgaris - Dormant Projects (Contd..3), H2 2015
Acne Vulgaris - Dormant Projects (Contd..4), H2 2015
Acne Vulgaris - Dormant Projects (Contd..5), H2 2015
Acne Vulgaris - Dormant Projects (Contd..6), H2 2015
Acne Vulgaris - Dormant Projects (Contd..7), H2 2015
Acne Vulgaris - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Acne Vulgaris, H2 2015
Number of Products under Development for Acne Vulgaris - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

COMPANIES MENTIONED

3SBio Inc.
Advancell
Allergan Plc
Almirall, S.A.
Biomar Microbial Technologies
Braintree Laboratories, Inc.
Brickell Biotech, Inc.
Celtaxsys, Inc.
Cosmo Pharmaceuticals S.p.A
Delenex Therapeutics AG
Deltanoid Pharmaceuticals Inc.
DermaXon, LLC
Dermira Inc.
ELORAC, Inc.
Ensol Biosciences Inc.
Foamix Pharmaceuticals Ltd.
Galderma S.A.
GlaxoSmithKline Plc
Helix BioMedix, Inc.
Hovione FarmaCiencia SA
Lee's Pharmaceutical Holdings Limited
Maruho Co., Ltd.
Novabiotics Limited
Novan, Inc.
OrigImm e.U.
Paratek Pharmaceuticals, Inc.
Phosphagenics Limited
Photocure ASA
Promius Pharma, LLC
Provectus Biopharmaceuticals, Inc.
RestorGenex Corporation
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
SkyePharma Plc
Telesso Technologies Limited
Thesan Pharmaceuticals, Inc.
Toyama Chemical Co., Ltd.
Valeant Pharmaceuticals International, Inc.
Venn Life Sciences Holdings Plc
Vyome Biosciences Private Limited
Xenon Pharmaceuticals Inc.
Skip to top


Acne Vulgaris - Pipeline Review, Q1 2011 US$ 500.00 Feb, 2011 · 54 pages
Pemphigus Vulgaris - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 25 pages
Pemphigus Vulgaris - Pipeline Review, Q2 2011 US$ 500.00 Apr, 2011 · 43 pages
Pemphigus Vulgaris – Pipeline Review, H2 2012 US$ 2,000.00 Dec, 2012 · 32 pages
Acne Vulgaris Global Clinical Trials Review, Q4, 2010 US$ 1,000.00 Dec, 2010 · 67 pages

Ask Your Question

Acne Vulgaris - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: